First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer

So Yeon Kim; Scott Gettinger

doi:10.1016/j.hoc.2023.02.008

First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer

Hematol Oncol Clin North Am. 2023 Jun;37(3):557-573. doi: 10.1016/j.hoc.2023.02.008.

Authors

So Yeon Kim¹, Scott Gettinger²

Affiliations

¹ Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. Electronic address: soyeon.kim@yale.edu.
² Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.

PMID: 37150586
DOI: 10.1016/j.hoc.2023.02.008

Abstract

Immunotherapy-based regimens are an established standard of care for the first-line treatment of driver-negative (EGFR/ALK/ROS WT) advanced non-small cell lung cancer. With multiple immune-based regimens approved in the first-line setting, clinicians are faced in practice with a variety of treatment choices. This article summarizes the most up-to-date trial data on treatments for driver-negative advanced non-small cell lung cancer, including immunotherapy monotherapy, chemoimmunotherapy, and combination immunotherapy, providing a framework for clinicians based on PD-L1 and smoking status. A multibiomarker assay that may best predict immunotherapy response remains an active area of research.

Keywords: Chemoimmunotherapy; Driver-negative advanced non–small cell lung cancer; Immunotherapy; Never-smoker; PD-L1; Smoker.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung* / therapy
Humans
Immunotherapy
Lung Neoplasms* / therapy

Substances

B7-H1 Antigen